Who
Michelle Robertson
Director
Company insider
Files Form 4 as: Director, Verastem; EVP, Chief Financial Officer, Geron; EVP, Chief Financial Officer, Editas Medicine; Chief Financial Officer, Momenta Pharmaceuticals.
In numbers
- Trades disclosed
- 61
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $753K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 17 Oct 2018
- Last trade
- 21 May 2026
- Last filed
- 26 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 May 2026filed 26 May 2026 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | GERN GeronBiotechnology | SEC FORM 4 Code M | —27,500 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | GERN GeronBiotechnology | SEC FORM 4 Sold | $19K9,855 at $1.94 | filing |
| 18 Feb 2026filed 19 Feb 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,500 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code M | —27,500 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | GERN GeronBiotechnology | SEC FORM 4 Code M | —27,500 at $0.00 | filing |
| 18 Feb 2026filed 19 Feb 2026 | GERN GeronBiotechnology | SEC FORM 4 Sold | $19K9,855 at $1.94 | filing |
| 17 Feb 2026filed 19 Feb 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,660,000 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,660,000 at $0.00 | filing |
| 22 May 2025filed 27 May 2025 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 22 May 2025filed 27 May 2025 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —8,333 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —656,000 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,500 at $0.00 | filing |
| 18 Jun 2024filed 20 Jun 2024 | VSTM VerastemBiotechnology | SEC FORM 4 Code A | —8,333 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 11 Mar 2024filed 13 Mar 2024 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,291 | filing |
| 11 Mar 2024filed 13 Mar 2024 | VSTM Verastemoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,291 | filing |
| 14 Feb 2024filed 16 Feb 2024 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —850,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.